STOCKWATCH: J&J points to medtech dip, Novartis lobs MS grenade to Teva
This article was originally published in Scrip
Executive Summary
Second-quarter earnings season kicked off properly this week with the world's largest healthcare company, Johnson & Johnson, reporting (scripintelligence.com, 16 July 2013). The healthcare conglomerate commonly known as J&J has a market capitalisation of nearly $260bn and is so diverse that it provides a window into other pure-play pharmaceutical, consumer, medical device and diagnostic companies, as well as a number of specific drugs, the revenues on which, much smaller companies are dependent.
